CD69 expression and tumour necrosis factor-α immunoreactivity in the inflammatory cell infiltrate of halo naevi

British Journal of Dermatology

Volumn 134, Issue 3, 1996, Pages 388-393

  Fernandez Herrera J ^a,b   Fernandez Ruiz E ^a   Lopez Cabrera M ^a   Garcia Diez A ^a   Sanchez Madrid F ^a   Gonzalez Amaro R ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CD8 ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; NEVUS; PRIORITY JOURNAL; SKIN INFLAMMATION; T LYMPHOCYTE;

EID: 9044228015     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1996.tb16219.x     Document Type: Article

References (38)

1. Sánchez-Mateos P, Sánchez-Madrid F. Structure-function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69. Eur J Immunol 1991; 21: 2317-25.
2. Cebrián M, Yagüe E, Rincón M et al. Triggering of T cell proliferation through AIM. an activation inducer molecule expressed on activated human lymphocytes. J Exp Med 1988; 168: 1621-37.
3. Hara T, Jung LKL, Bjorndahl JM, Fu SM. Human T cell activation. III. Rapid induction of a phosphorylated 28kD/32kD disulfide-linked early activation antigen (EA 1) by 12-O-tetradecanoyl phorbol-13-acetate, mitogens, and antigens. J Exp Med 1986; 164: 1988-2005.
4. Lanier LL, Buck DW, Rhodes L et al. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J Exp Med 1988; 167: 1572-85.
5. Risso A, Cosulich ME, Ruhartelli A et al. MLR3 molecule is an activation antigen shared by human B, T lymphocytes and T cell precursors. Eur J Immunol 1989; 19: 323-8.
6. Testi R, Pulcinelli F, Frati L et al. CD69 is expressed on platelets and mediates platelet activation and aggregation. J Exp Med 1990; 172: 701-7.
7. Bieber T, Rieger A, Stingl G et al. CD69, an early activation antigen on lymphocytes, is constitutively expressed by human epidermal Langerhans cells. J Invest Dermatol 1992; 98: 771-6.
8. Sánchez-Mateos P, Cebrián M, Acevedo A et al. Expression of a gp 33/27000MW activation inducer molecule (AIM) on human lymphoid tissues. Induction of cell proliferation on thymocytes and B lymphocytes by anti-AIM antibodies. Immunology 1989; 68: 72-9.
9. Testi R, Phillips JH, Lanier LL. Constitutive expression of phosphorylated activation antigen (Leu 23) by CD3 human thymocytes. J Immunol 1988; 141: 2557-63.
10. López-Cabrera M, Santis AG, Fernandez-Ruiz E et al. Molecular cloning, expression, and chromosomal localization of the human earliest activation antigen AIM/CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993; 178: 537-47.
11. Jamann J, Fiebig H, Strauss M. Expression cloning of the early activation antigen CD69, a type II integral membrane protein with a C-type lectin domain. J Immunol 1993; 150: 4920-7.
12. Ziegler SF, Ramsdell F, Hjerrild KA et al. Molecular characterization of the early activation antigen CD69: a type II membrane glycoprotein related to a family of natural killer cell activation antigens. Eur J Immunol 1993; 23: 1643-8.
13. Testi R, Phillips JH, Lanier LL. T cell activation via Leu-23 (CD69). J Immunol 1989; 143: 1123-8.
14. Santis AG, Campanero MR, Alonso JL et al. Tumor necrosis factor-α production induced in T lymphocytes through the AIM/CD69 activation pathway. Eur J Immunol 1992; 22: 1253-60.
15. Tugores A, Alonso MA, Sánchez-Madrid F, de Landázuri MO. Human T cell activation through the activation-inducer molecule/CD69 enhances the activity of transcription factor AP-1, J Immunol 1992; 148: 2300-6.
16. Moretta A, Poggi A, Pende D et al. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolylic T lymphocytes expressing T cell receptor α/β. J Exp Med 1991; 174: 1393-8.
17. Rhodes AR. Neoplasms: benign neoplasias, hyperplasias and dysplasias of melanocytes. In: Dermatology in General Medicine (Fitzpatrick TB, Eisen AZ, Wolff K et al., eds), 4th edn. New York: McGraw-Hill. 1993. pp. 996-1077.
18. Wayte DM, Helwig EB, Halo nevi. Cancer 1968; 22: 69-90.
19. Jacobsen JB, Edelstein LM, Snijder LM, Fortier N. Ultrastructural evidence for destruction in the halo vevus. Cancer Res 1975; 35: 352-7.
20. Copeman PWM, Lewis MG, Phillips TM, Elliot PG. Immunological association of the halo naevus with cutaneous malignant melanoma. Br J Dermatol 1973; 88: 127-37.
21. Roenigk HH, Deodhar SD, Krebs JA, Barna B. Microcytotoxicity and serum blocking factors in malignant melanoma and halo nevus. Arch Dermatol 1975; 111: 720-5.
22. Mitchell MS, Nordlund JJ, Lerner AB. Comparison of cell mediated immunity to melanoma cells in patients with vitiligo, halo nevi or melanoma. J Invest Dermatol 1980; 75: 144-7.
23. Epstein WL, Sagabeil R, Spliter L. Halo nevi and melanoma. JAMA 1973; 225: 373-7.
24. Bergman W, Willemze R, de Graaft-Reitsma C, Ruiter DJ. Analysis of major histocompatibility antigens and the mononuclear cell infiltrate in halo nevi. J Invest Dermatol 1985; 85: 25-8.
25. Brocker EB, Suter L, Sorg C. HLA-DR antigen expression in primary melanomas of the skin. J Invest Dermatol 1984; 82: 244-7.
26. Poppema S, Brovker EB, de Ley L et al. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol 1983; 51: 77-82.
27. Kornstein MJ, Brooks I, Elder DE. Immunoperoxidase localization of lymphocyte subsets in the host response to melanoma an nevis. Cancer Res 1983; 43: 2749-53.
28. Tokura Y, Yamanaka K, Wakita H et al. Halo congenital nevus undergoing spontaneous regression. Involvement of T cell immunity in involution and presence of circulating anti-nevus cell IgM antibodies. Arch Dermatol 1994; 130: 1036-41.
29. Akasu R, From Y, Kahn H. Characterization of the mononuclear infiltrate involved in regression of halo nevi. J Cutan Pathol 1994; 21: 302-11.
30. Sánchez-Madrid F, Toribio ML, Gambón F, de Landázuri MO. Cell surface molecular changes in the activation of human thymocytes. J Immunol 1985; 135: 3938-43.
31. Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L et al. Induction of tumor necrosis factor-α production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994; 179: 841-8.
32. Acevedo A, del Pozo MA, Arroyo AG et al. Distribution of ICAM-3 bearing cells in normal human tissues. Expression of a novel counter-receptor for LFA-1 in epidermal Langerhans cells. Am J Pathol 1993; 143: 774-83.
33. + T lymphocytes in the inflammatory infiltrate in virus-related chronic active hepatitis. Gastroenterology 1990; 98: 126-32.
34. Laffon A, Garcia-Vicuña R, Humbria A et al. Up-regulated expression and function of VLA-4 fibronectin receptors on human activated T cell in rheumatoid arthritis. J Clin Invest 1991; 88: 546-50.
35. Yokoyama WM. Recognition structures on natural killer cells. Curr Opin Immunol 1993; 5: 67-73.
36. Deeper JM, Leonard WJ, Kronke MJ. Regulation of interleukin-2 receptor expression: effect of phorbol diester, phospholipase C, and reexposure to lectin or antigen. J Immunol 1984; 133: 3054-61.
37. Kriegler M, Perez C, deFay K et al. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 1988; 53: 45-53.
38. Khinkhabwala M, Sehajpal P, Skolnik E et al. A novel addition to the T cell repertory. Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J Exp Med 1990; 171: 941-6.